239 related articles for article (PubMed ID: 21457145)
1. RAGE biology, atherosclerosis and diabetes.
Barlovic DP; Soro-Paavonen A; Jandeleit-Dahm KA
Clin Sci (Lond); 2011 Jul; 121(2):43-55. PubMed ID: 21457145
[TBL] [Abstract][Full Text] [Related]
2. An update on advanced glycation endproducts and atherosclerosis.
Del Turco S; Basta G
Biofactors; 2012; 38(4):266-74. PubMed ID: 22488968
[TBL] [Abstract][Full Text] [Related]
3. Advanced glycation end products: sparking the development of diabetic vascular injury.
Goldin A; Beckman JA; Schmidt AM; Creager MA
Circulation; 2006 Aug; 114(6):597-605. PubMed ID: 16894049
[TBL] [Abstract][Full Text] [Related]
4. Advanced glycation end products and diabetic foot disease.
Huijberts MS; Schaper NC; Schalkwijk CG
Diabetes Metab Res Rev; 2008; 24 Suppl 1():S19-24. PubMed ID: 18442180
[TBL] [Abstract][Full Text] [Related]
5. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications.
Yamagishi S
Ther Apher Dial; 2009 Dec; 13(6):534-9. PubMed ID: 19954478
[TBL] [Abstract][Full Text] [Related]
6. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
Yamagishi S
Exp Gerontol; 2011 Apr; 46(4):217-24. PubMed ID: 21111800
[TBL] [Abstract][Full Text] [Related]
7. Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis.
Kim W; Hudson BI; Moser B; Guo J; Rong LL; Lu Y; Qu W; Lalla E; Lerner S; Chen Y; Yan SS; D'Agati V; Naka Y; Ramasamy R; Herold K; Yan SF; Schmidt AM
Ann N Y Acad Sci; 2005 Jun; 1043():553-61. PubMed ID: 16037278
[TBL] [Abstract][Full Text] [Related]
8. The AGE/RAGE axis in diabetes-accelerated atherosclerosis.
Jandeleit-Dahm K; Watson A; Soro-Paavonen A
Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):329-34. PubMed ID: 18290873
[TBL] [Abstract][Full Text] [Related]
9. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury.
Soulis T; Thallas V; Youssef S; Gilbert RE; McWilliam BG; Murray-McIntosh RP; Cooper ME
Diabetologia; 1997 Jun; 40(6):619-28. PubMed ID: 9222639
[TBL] [Abstract][Full Text] [Related]
10. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
Yamagishi S; Ueda S; Okuda S
Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis.
Ihara Y; Egashira K; Nakano K; Ohtani K; Kubo M; Koga J; Iwai M; Horiuchi M; Gang Z; Yamagishi S; Sunagawa K
J Mol Cell Cardiol; 2007 Oct; 43(4):455-64. PubMed ID: 17761193
[TBL] [Abstract][Full Text] [Related]
12. RAGE, vascular tone and vascular disease.
Farmer DG; Kennedy S
Pharmacol Ther; 2009 Nov; 124(2):185-94. PubMed ID: 19616578
[TBL] [Abstract][Full Text] [Related]
13. Blood cells and vascular cell interactions in diabetes.
Wautier JL; Wautier MP
Clin Hemorheol Microcirc; 2001; 25(2):49-53. PubMed ID: 11790870
[TBL] [Abstract][Full Text] [Related]
14. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.
Yamagishi S; Takeuchi M; Inagaki Y; Nakamura K; Imaizumi T
Int J Clin Pharmacol Res; 2003; 23(4):129-34. PubMed ID: 15224502
[TBL] [Abstract][Full Text] [Related]
15. Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease.
Nishizawa Y; Koyama H
J Ren Nutr; 2008 Jan; 18(1):76-82. PubMed ID: 18089449
[TBL] [Abstract][Full Text] [Related]
16. The RAGE axis and endothelial dysfunction: maladaptive roles in the diabetic vasculature and beyond.
Ramasamy R; Yan SF; Schmidt AM
Trends Cardiovasc Med; 2005 Oct; 15(7):237-43. PubMed ID: 16226677
[TBL] [Abstract][Full Text] [Related]
17. RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice.
Sun L; Ishida T; Yasuda T; Kojima Y; Honjo T; Yamamoto Y; Yamamoto H; Ishibashi S; Hirata K; Hayashi Y
Cardiovasc Res; 2009 May; 82(2):371-81. PubMed ID: 19176597
[TBL] [Abstract][Full Text] [Related]
18. RAGE axis: Animal models and novel insights into the vascular complications of diabetes.
Naka Y; Bucciarelli LG; Wendt T; Lee LK; Rong LL; Ramasamy R; Yan SF; Schmidt AM
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1342-9. PubMed ID: 15155381
[TBL] [Abstract][Full Text] [Related]
19. Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats.
Yamagishi S; Matsui T; Nakamura K; Yoshida T; Takeuchi M; Inoue H; Yoshida Y; Imaizumi T
Ophthalmic Res; 2007; 39(2):92-7. PubMed ID: 17284935
[TBL] [Abstract][Full Text] [Related]
20. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes.
Rojas A; Morales MA
Life Sci; 2004 Dec; 76(7):715-30. PubMed ID: 15581904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
